Adenoviral-mediated p53 transgene expression sensitizes both wild-type and null p53 prostate cancer cells in vitro to radiation

This publication has 17 references indexed in Scilit:

• The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
• Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
• Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation
  Cancer, 1997
• Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
• Recombinant adenovirus vector expressing wildtype p53 is a potent inhibitor of prostate cancer cell proliferation
  Urology, 1995
• Radiation-induced apoptosis: Relevance to radiotherapy
  International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
• Safety Evaluation of Ad5CMY- p53 In Vitro and In Vivo
  Human Gene Therapy, 1995
• Radical Prostatectomy for High Grade Disease: A Reevaluation 1994
  Journal of Urology, 1994
• p53 is required for radiation-induced apoptosis in mouse thymocytes
  Nature, 1993
• Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
  Nature, 1991